Drug Information

Drug General Information
Drug ID
D0V4IQ
Former ID
DIB012979
Drug Name
RhGDF-5
Synonyms
MD-05; MD-06; MD-07; MD-08; RhGDF-5 (bone regeneration); MP52 (BCP carrier, bone regeneration), BioPharm/Scil; RhGDF-5 (bone regeneration), Scil/Medtronic; RhGDF-5 (implantable bone substitute), BioPharm/Scil; MP52 (beta-tricalciumphosphate carrier, bone regeneration), BioPharm/Scil
Indication Periodontal disease [ICD10:K05] Phase 2 [523045]
Company
Biopharm GmbH
Target and Pathway
Target(s) Growth differentiation factor-5 Target Info Modulator [528413]
KEGG Pathway Cytokine-cytokine receptor interaction
TGF-beta signaling pathway
Hippo signaling pathway
NetPath Pathway IL1 Signaling Pathway
TGF_beta_Receptor Signaling Pathway
PANTHER Pathway TGF-beta signaling pathway
Reactome Molecules associated with elastic fibres
WikiPathways Differentiation Pathway
Elastic fibre formation
References
Ref 523045ClinicalTrials.gov (NCT01124006) A Multicenter, Randomized, Double-blind, Placebo Controlled, Clinical Trial to Evaluate the Safety, Tolerability and Preliminary Effectiveness of 2 Doses of Intradiscal rhGDF-5 (Single Administration) for the Treatment of Early Stage Lumbar Disc Degeneration. U.S. National Institutes of Health.
Ref 528413Superior effect of MD05, beta-tricalcium phosphate coated with recombinant human growth/differentiation factor-5, compared to conventional bone substitutes in the rat calvarial defect model. J Periodontol. 2006 Sep;77(9):1582-90.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.